Hematocrit on TRT: Why It Rises and How It's Monitored

Testosterone stimulates the body to make more red blood cells, so hematocrit, the share of your blood made up of red cells, commonly rises on testosterone replacement therapy (TRT). A higher hematocrit thickens the blood, which can raise the risk of clots, so it is the single most closely monitored lab on TRT. Management is provider-directed and may involve adjusting the dose, spacing injections, changing route, or therapeutic phlebotomy. TRT is a prescription medical therapy (testosterone is a Schedule III controlled substance) that requires a diagnosis and ongoing lab monitoring by a licensed clinician, and interpreting these numbers is your clinician's job, not yours.

What hematocrit is and why testosterone raises it

Hematocrit is the percentage of your blood volume that is red blood cells. A typical adult male range sits roughly in the low-to-mid 40s percent, though labs vary, and this is general reference, not a personal target.

Testosterone drives erythropoiesis, the production of red blood cells. It does this in part by increasing erythropoietin (EPO), the hormone that signals red cell production, and by improving iron availability for making hemoglobin. This is a normal, expected physiological effect of testosterone, not a sign something has gone wrong. It simply needs to be watched, because the same mechanism that can improve symptoms of low testosterone also pushes red cell counts upward.

When hematocrit climbs too high, the condition is called erythrocytosis, or polycythemia when it is more pronounced. The practical concern is viscosity: blood with a higher red cell fraction is thicker and flows less easily.

Why elevated hematocrit matters

This is one of the most clinically significant risks of TRT, and it should not be minimized. Thicker, more viscous blood is associated with a higher risk of thrombotic events, meaning clots that can cause stroke, deep vein thrombosis (DVT), pulmonary embolism (PE), or heart attack.

The magnitude is real. A 2025 meta-analysis of 51 randomized controlled trials, published in the American Society of Hematology's journal Blood Advances, found that testosterone therapy increased the risk of polycythemia (hematocrit above roughly 52 to 54 percent) with a risk ratio of about 3.69 compared with placebo. In plain terms, TRT meaningfully raises the odds of crossing into the elevated-hematocrit zone, which is exactly why monitoring exists.

It is worth being clear about what this does and does not mean. A rising hematocrit is a manageable, monitorable risk, not a reason to panic, and most people on well-monitored TRT never reach a dangerous level. The danger comes from running TRT unmonitored and letting hematocrit drift high unnoticed, which is the scenario responsible bloodwork is designed to prevent. Our TRT bloodwork guide covers where hematocrit sits among the full panel.

What levels prompt concern

There is no single universal number, and the threshold for action is a clinical judgment your provider makes in the context of your history. As general reference only:

US clinical practice often becomes attentive as hematocrit approaches 50 to 52 percent, which is a relatively conservative posture. The Endocrine Society's testosterone therapy guideline has advised withholding therapy if hematocrit rises above 54 percent, allowing it to normalize, and then resuming at a lower dose. European guidance has also commonly used 54 percent as an upper limit. These figures are reference points discussed with clinicians, not lines you should manage yourself.

Several factors make a higher hematocrit response more likely, and a clinician will factor them in: older age, obstructive sleep apnea, smoking, higher testosterone doses, and the injectable route compared with topical preparations. Someone with sleep apnea who smokes is in a different risk position than someone without those factors, even on the same dose.

How hematocrit is monitored

Hematocrit is part of a complete blood count (CBC), drawn as part of routine TRT labs. A typical monitoring rhythm, which your provider individualizes, checks it at baseline before starting, then around the three-, six-, and twelve-month marks in the first year, and at least annually after that. People with higher readings or more risk factors are often checked more frequently.

The value of monitoring is in the trend, not any single draw. A one-off reading can be nudged by dehydration or even how long a tourniquet was on, so what your clinician really watches is the direction and pace of change over multiple draws. A hematocrit creeping steadily upward over three checks tells a different story than a single borderline value that settles back down.

This is precisely the kind of pattern that gets lost in a folder of PDFs. Logging each CBC result over time turns scattered lab slips into a readable trendline, which is one of the things Myo is built to do: store each panel and chart markers like hematocrit and hemoglobin draw over draw, so a slow climb is visible early enough to act on. Myo tracks the data your clinician directs; it does not interpret your labs or change your dose.

How elevated hematocrit is managed

When hematocrit rises into the range a clinician wants to address, several provider-led levers exist. None of these are things to attempt on your own.

Dose reduction. Lowering the testosterone dose reduces the erythropoietic stimulus and is often the first adjustment.

Spacing the dose. Splitting the same weekly amount into more frequent, smaller injections can blunt the peak testosterone levels that may drive red cell production. This overlaps with the broader frequency discussion in our dosing frequency guide.

Changing route. Some clinicians and patients report lower hematocrit on subcutaneous rather than intramuscular injection, though the evidence is mixed and individual.

Therapeutic phlebotomy. Removing a unit of blood, similar to a donation, directly lowers hematocrit and is used in some protocols, often discussed when hematocrit climbs above roughly 52 percent. It works, but the long-term evidence for phlebotomy versus simply reducing the dose is not fully established, so it is a tool a clinician chooses deliberately rather than a default. Frequent phlebotomy also has its own downsides, such as iron depletion, which is another reason it belongs under supervision.

The honest summary is that elevated hematocrit on TRT is common, monitorable, and usually manageable, but only inside a structure of regular bloodwork and provider-directed adjustment. That structure is the whole point.

Hematocrit, hemoglobin, and red cell count: reading the CBC

People sometimes fixate on hematocrit alone, but a clinician reads it alongside two related numbers on the complete blood count: hemoglobin and red blood cell count. Hemoglobin is the oxygen-carrying protein inside red cells, and it tends to move in the same direction as hematocrit, so a rising hemoglobin usually accompanies a rising hematocrit. Looking at both helps a clinician confirm a trend is real rather than a fluke of a single draw.

This matters because of how easily a single hematocrit reading can mislead. Dehydration concentrates the blood and can push hematocrit up artificially, while being well hydrated can nudge it down, which is one reason your clinician cares about consistency in how and when blood is drawn. A value that looks alarming on a day you came in dehydrated may settle when you are properly hydrated, and only repeated measurement separates a true upward trend from day-to-day noise. That is the practical case for tracking the whole CBC over time rather than reacting to one number.

Route and frequency: why they enter the conversation

Two of the levers above, route and frequency, deserve a little more explanation because they come up constantly in TRT discussions, and because the reasoning behind them is often garbled online.

The frequency idea rests on peaks. A single large weekly injection produces a higher testosterone peak in the days after the shot than the same weekly amount split into smaller, more frequent doses. Since the erythropoietic drive is thought to track with testosterone exposure, smoothing out those peaks may, for some people, soften the push on red cell production. This is the same logic that drives much of the dosing frequency discussion, where stability is the recurring theme.

The route idea is similar but less settled. Some clinicians and patients report that subcutaneous injection produces a lower hematocrit than intramuscular injection of the same dose, possibly because of differences in absorption and peak levels. The data here is genuinely mixed, so it is best treated as something a clinician might try for an individual rather than a rule. The broader point is that these are tools a provider reaches for based on your specific labs, not switches you flip on your own.

Risk factors that change the picture

Not everyone responds to testosterone the same way, and a careful clinician weighs the factors that make a steeper hematocrit rise more likely. Older age is associated with a higher response. Obstructive sleep apnea is a notable one, because the low overnight oxygen levels it causes independently stimulate red cell production, so testosterone stacked on top of untreated sleep apnea compounds the effect. Smoking does the same through chronic low-grade oxygen deprivation, and higher testosterone doses naturally drive a larger response than conservative ones.

This is part of why the same dose can be unremarkable for one person and a problem for another. It also explains why a thorough provider asks about sleep, snoring, and smoking before and during TRT, and may push harder on managing those issues rather than treating the hematocrit number in isolation. Untreated sleep apnea, in particular, is worth addressing on its own merits, and doing so can make the hematocrit side of TRT more manageable too.

What to ask a provider

Useful questions for a clinician include: What is my baseline hematocrit, and what level would prompt you to act? How often will we recheck it given my risk factors? If it rises, would you adjust my dose, my frequency, my route, or consider phlebotomy first? And do I have risk factors, like sleep apnea, that change the picture? A provider experienced in hormonal health can answer these against your actual numbers.

The tracking angle

Hematocrit is a trend, and trends are only as good as the record behind them. Myo stores each TRT lab panel and charts hematocrit and hemoglobin over time, so what would otherwise be a year of loose lab slips becomes one chart you can hand your prescriber. It also keeps that next to your injection log and side-effect tracking, so if symptoms and a rising hematocrit line up, the timeline is right there. Myo organizes a provider-directed protocol; it never prescribes, recommends a dose, or interprets your results.

References

• Ory J, et al. Diagnosis, management, and outcomes of drug-induced erythrocytosis. Blood Advances (American Society of Hematology), 2025.
• Endocrine Society. Testosterone Therapy in Men With Hypogonadism: Clinical Practice Guideline. endocrine.org.
• PMC. Therapeutic phlebotomy for testosterone-induced erythrocytosis, 2024.
• US FDA. Testosterone prescribing information and monitoring guidance. accessdata.fda.gov.